Sign in to view content

Visual Impact of Central Subfield Thickness (CST) Fluctuation in Patients With nAMD Treated With Anti-VEGFs in VIEW Trials

Dilsher S. Dhoot, MD

Video
Published 2021

Related

Outcomes of Patients with DME and Baseline BCVA 20/50 or Worse or 20/40 or Better Treated with Aflibercept 8 mg and 2 mg in the Phase 2/3 PHOTON Trial
Diana V Do, MD, FASRS
Updates from the Field
2024
Subretinal Aflibercept vs Ranibizumab vs Bevacizumab in the Context of PPV: Pneumatic Displacement With Subretinal Air and tPA in Naïve Submacular Hemorrhage Due to nAMD
Matias Iglicki, MD
Annual Meeting Talks
2024
Economic Benefit of Higher Durability Anti-VEGF Agents in the Treatment of Neovascular Macular Degeneration
Sabin Dang, MD
Annual Meeting Talks
2023

Category: AMD-Neovascular

See more